Additionally, tumor-associated aged neutrophils (CXCR4+CD62Llow) affected by tumor-derived nicotinamide phosphoribosyltransferase (NAMPT) form two distinct types of NETs: mitochondrial-dependent vital NETs, driven by sirtuin (SIRT)1 to release mitochondrial DNA, and traditional Cit-Histone H3-dependent fatal NETs, which suggest that targeting the NAMPT–SIRT1–NET axis could be a therapeutic target [132]. This evidence concerns the gene SIRT1 and neoplasm.